This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Sai Reddy, PhD
Associate Professor, Department of Biosystems Science and Engineering at ETH Zurich at ETH Zurich


Sai Reddy is an Associate Professor in the Department of Biosystems Science & Engineering, ETH Zurich, Switzerland. His research group uses methods in systems and synthetic biology to study and manipulate immune responses for applications in biotechnology, vaccination, and immunotherapy. Sai Reddy holds B.S. (2003) and M.S. (2004) in Biomedical Engineering from Northwestern University (Evanston, IL, USA). He completed his Ph.D. thesis at Ecolé Polytechnique Féderale de Lausanne (EPFL, Switzerland) in Bioengineering and Biotechnology (2008). Sai Reddy did post-doctoral research at the University of Texas, Austin (2008-2011).

Agenda Sessions

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A and Audience Interaction - Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A and Audience Interaction - Nanobodies: In Which Applications Will They Make a Difference?

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #4: ADVANCES IN COMPUTATIONAL AND MACHINE LEARNING APPROACHES FOR ANTIBODY ENGINEERING - To prepare for this discussion/Q&A, attendees should view the presentations from Session #4 in the Watch On-Demand Sessions Tab prior to this session

  • SESSION CHAIR: Mark Your Calendar for Tuesday, August 25, 11:15-12:00 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel

    On Demand
  • “Hot Topic” Discussion Session: Immunogenicity and Anti-drug Antibodies (ADA) Following Therapeutic mAb Administration